Anti-inflammatory compositions and methods

A compound of formula I:

• R1—NH—CO—NH-Q-R2 (I)
• or a pharmaceutically acceptable salt thereof
• wherein
• R1 s a lower C2–C5 alkyl group, straight or branched chain and optionally substituted by an amino group of formula —NR3R4, wherein R3 and R4 are independently H, or C1–C3 alkyl group;
• Q is either a bond or a divalent C1–C5 straight or branched alkyl or aikenyl group;
• R2 is one of the following groups
• a. C5–C10 heteroaryl group selected from furanyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, dithiolyl, oxathiolyl, isoxazolyl, piridazinyl, pyrimidinyl, pyrazinyl, indolyl, isoquinolinyl, benzimidazolyl, benzoxaziyl, benzothiadiazolyl nanhthyridinyl, pyrido[3,4-b]pyridinyl, pyrido[3,2-b]b pyridinyl, pyrido[4,3-b]hyridinyl, and 4-aminopyrazolo[3,4d]pyrimidinyl
• b. C5–C10 heterocyclic group selected from piperazyl, tetahydrofuranyl, dioxanyl, wherein the heteroaryl, or heterocyclic ring is unsubstituted or substituted by one or more of the following groups
• i. R5, —CN, Halogen, OR5, —COR5, —CO2R5, OCF3, —CONH2, —SO2NH2, and NO2, wherein R5 is a C1 to C4 straight or branched alkyl group, and
• c. N6R 7, wherein R6 and R7 are
• together with the N forming a 5 or 6 membered monocyclic ring having one or more ring positions occupied by another N, S, or O, wherein the heteroaryl ring thus formed is unsubstituted or substituted by one or more of the following groups
• 1. R5, —CN, halogen, OR5, —COR5, —CO2R5, OCF3, —CONH2, —SO2NH2,
• 2. C1–C5 aikyl or alkylene group substituted by an aryl group, and
• 3. C6 or C10 aryl or heteroaryl group unsubstituted or substituted by one ore more of R5, CF3, and halogen, wherein the aryl or hetero aryl may be a pending group off one position of, or a fused with, the NR6R7 ring.